Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis

27 May 2018 (09:45 - 09:55)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Michel Komajda

Groupe Hospitalier Paris Saint-Joseph, Paris (France)

11 More presentations in this session

Presentation thumbnail

The HF-Wii study: Improving exercise capacity of patients with heart failure through exergaming: Secondary outcomes and per protocol analysis of an international multicenter RCT

Professor T. Jaarsma (Linkoping, SE)

Presentation thumbnail

Discussion - HF-Wii

Presentation thumbnail

Diabetes and obesity in heart failure: a crossroads for prognosis and the efficacy of beta-blockers

Professor D. Kotecha (Birmingham, GB)

Presentation thumbnail

Discussion - BB-meta-HF

Presentation thumbnail

Phase ii trial of pharmacogenetic guided beta-blocker therapy with bucindolol vs. metoprolol for the prevention of atrial fibrillation/flutter in heart failure: GENETIC-AF

Professor W. Abraham (Columbus, US)

Access the full session

Session thumbnail

Late breaking trial II - Chronic heart failure

The Event

Heart Failure 2018

27 May 2018 09:45 CET

You may be interested in

Congress Presentation

Incremental efficacy of medical therapy for chronic heart failure with a reduced ejection fraction: a systematic review and network meta-analysis

1 July 2021

Congress Session

Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond

20 May 2025

Congress Session

Diagnostic and prognostic biomarkers in heart failure (2)

30 August 2026

Congress Session

Navigating through heart failure device therapies

18 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources